Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

21.3%

33 terminated/withdrawn out of 155 trials

Success Rate

56.6%

-30.0% vs industry average

Late-Stage Pipeline

12%

19 trials in Phase 3/4

Results Transparency

107%

46 of 43 completed trials have results

Key Signals

41 recruiting46 with results30 terminated

Enrollment Performance

Analytics

Phase 1

67(43.8%)

Phase 2

66(43.1%)

Phase 3

18(11.8%)

N/A

1(0.7%)

Phase 4

1(0.7%)

153Total

Phase 1(67)

Phase 2(66)

Phase 3(18)

N/A(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (155)

Showing 20 of 155 trials

NCT07049926Phase 1Recruiting

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

Role: collaborator

NCT05176483Phase 1Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Role: lead

NCT03170960Phase 1Active Not Recruiting

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Role: lead

NCT07845786Phase 2Not Yet Recruiting

Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Role: lead

NCT06943755Phase 2Recruiting

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Role: lead

NCT07489495Phase 3Recruiting

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

Role: collaborator

NCT07193550Phase 2Recruiting

A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)

Role: collaborator

NCT03899155Phase 2Recruiting

Pan Tumor Rollover Study

Role: collaborator

NCT06863311Phase 2Recruiting

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

Role: collaborator

NCT07750158Phase 3Recruiting

Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

Role: lead

NCT05048212Phase 2Recruiting

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

Role: collaborator

NCT04412629Phase 2Active Not Recruiting

Cabozantinib in High Grade Neuroendocrine Neoplasms

Role: collaborator

NCT07428616Phase 2Recruiting

A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

Role: lead

NCT05502315Phase 2Active Not Recruiting

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

Role: collaborator

NCT06902376Phase 1Recruiting

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Role: collaborator

NCT06959511Phase 2Recruiting

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Role: collaborator

NCT06794229Phase 2Recruiting

Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis

Role: collaborator

NCT06968988Phase 1Suspended

Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

Role: collaborator

NCT06156410Phase 1Recruiting

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

Role: collaborator

NCT07185945Phase 2Not Yet Recruiting

Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy

Role: collaborator